BioNTech SE (BNTX)

163.22
+0.22(+0.14%)
समय के बाद
161.50
-1.72(-1.05%)
- रियल टाइम डेटा
  • वॉल्यूम:
    780,160
  • दिन की रेंज:
    161.14 - 166.49
  • 52 सप्ताह रेंज:
    121.32 - 462.56

BNTX समीक्षा

पिछला बंद
163
दिन की रेंज
161.14-166.49
आय
26.5B
खुला
166.39
52 सप्ताह रेंज
121.32-462.56
ईपीएस
54.01
वॉल्यूम
780,160
मार्केट कैप
39.67B
लाभांश (यील्ड)
1.5342
(0.94%)
औसत वॉल्यूम (3एम)
1,586,596
पी/ई अनुपात
3.02
बीटा
-
1- वर्ष बदलाव
-16.59%
बकाया शेयर
243,019,216
अगली कमाई तिथि
07 अग॰ 2022
BioNTech पर आपकी भावना क्या है?
या
अभी बाज़ार बंद हैं। वोटिंग बाजार का समय के दौरान खुली है।

BioNTech SE समाचार

BioNTech SE विश्लेषण

BioNTech SE कंपनी प्रोफाइल

BioNTech SE कंपनी प्रोफाइल

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

और पढ़ें

तकनीकी सारांश

प्रकार
5 मिनट
15 मिनट
प्रति घंटा
दैनिक
मासिक
मूविंग एवरेजखरीदेंखरीदेंखरीदेंखरीदेंखरीदें
तकनीकी संकेतकबेचनामजबूत विक्रयबेचनामजबूत खरीदतटस्थ
सारांशतटस्थतटस्थतटस्थमजबूत खरीदतटस्थ